Newsfiscal.ai
Allogene Therapeutics Announces Participation in SITC 2026 Annual Meeting
· Published
Article summary
Allogene Therapeutics, Inc. announced its participation in the Society for Immunotherapy of Cancer (SITC) Annual Meeting, featuring two invited presentations and a preclinical poster.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…